Semaglutide vs Metformin for Weight Loss — Which Is Better?

The short answer: semaglutide wins on weight loss, metformin wins on cost

Semaglutide produces dramatically more weight loss than metformin — roughly 15% of body weight versus 3–5% for metformin. There's no clinical question about which is more effective for weight loss. The comparison is relevant because metformin is frequently prescribed first, is extremely cheap, and is familiar to most physicians. Understanding what each does — and doesn't do — helps you have a better conversation with your provider.

How they work differently

Metformin primarily works in the liver — reducing the liver's glucose output and improving how cells respond to insulin. It has modest effects on appetite and weight that are secondary to its metabolic action. The weight loss from metformin is real but modest, averaging 3–5 kg (7–11 lbs) over 12 months in clinical studies.

Semaglutide works primarily in the brain and gut — mimicking the GLP-1 hormone to directly suppress appetite, reduce cravings, slow gastric emptying, and improve insulin signaling. Weight loss from semaglutide comes primarily from eating less, not just from better insulin utilization. This is why the results are so dramatically different despite both drugs affecting insulin metabolism.

Head-to-head comparison

When metformin makes sense over semaglutide

• Cost is the primary constraint: At $4–15/month, metformin is accessible to virtually everyone. If the goal is meaningful but modest weight loss with maximum affordability, metformin is a legitimate starting point
• Needle aversion is significant: Metformin is an oral pill. For patients with strong aversion to injections who can't tolerate the idea of weekly self-injection, metformin provides some benefit without the injection barrier
• PCOS management: Metformin is the established first-line treatment for PCOS-related insulin resistance and is extremely well-studied in this context. It's frequently prescribed alongside GLP-1 therapy for PCOS, not instead of it
• Physician preference for established medications: Many primary care physicians are more comfortable prescribing metformin for weight-related concerns than newer GLP-1 medications. If your doctor recommends starting there, it's not unreasonable to try

When semaglutide makes sense over metformin

For patients whose primary goal is meaningful weight loss — not just modest metabolic improvement — semaglutide is the clear clinical choice. The 3–5x difference in weight loss outcomes is clinically significant. Metformin producing 3–5% weight loss versus semaglutide's 15% isn't a close comparison when substantial weight loss is the goal.

If you've already tried metformin for weight management and achieved limited results, this is exactly the situation where moving to a GLP-1 medication makes clinical sense. Many patients transition from metformin to semaglutide (or add semaglutide to existing metformin) when their weight loss goals require more than metformin can deliver.

What the clinical data actually shows

The comparison is straightforward in the trial data. The STEP-1 trial showed semaglutide 2.4mg producing 14.9% average weight loss at 68 weeks. The best metformin weight loss data shows 2–3% over 12 months. There is no scenario in which metformin matches semaglutide for weight loss — the gap is too large and too consistent across multiple trials.

For blood sugar control in type 2 diabetes, metformin remains the standard first-line agent with decades of safety data and a 2024 ADA consensus endorsing it as initial therapy. Semaglutide produces superior HbA1c reduction (1.5–1.8 percentage points in STEP-2) versus metformin's typical 1–1.5%, and adds cardiovascular protection (SUSTAIN-6 trial: 26% reduction in major adverse cardiovascular events).

The honest cost comparison

Can you take semaglutide and metformin together?

Yes — and this is common practice for type 2 diabetes. Metformin is typically the first medication started; semaglutide is added when additional glycemic control or weight management is needed. The combination produces additive HbA1c reduction and the STEP-2 trial specifically enrolled patients on metformin background therapy. Many patients are on both simultaneously.

For weight loss without diabetes, combining semaglutide with metformin is less common but occasionally prescribed — some physicians use metformin's modest insulin-sensitizing effect as an adjunct. This is off-label use for metformin in that context.

Who should choose semaglutide vs metformin

• Choose semaglutide if: meaningful weight loss is the goal (metformin simply cannot achieve 15%), you have type 2 diabetes with cardiovascular disease, or you've been on metformin with insufficient results and need more glycemic control
• Choose metformin if: cost is the primary constraint ($4/month vs $249+), you have mild type 2 diabetes as the primary concern without significant weight loss goals, or you want the agent with the longest safety track record in diabetes care
• Consider both: most type 2 diabetes patients who need semaglutide stay on metformin as the foundation and add semaglutide for additional efficacy